Cybin Inc (CYBN) Stock Price, Quote & News

Company Profile

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical...

Industry: Biotechnology

Sector: Healthcare

Website: cybin.com

Address:

100 King Street West, Suite 5600, Toronto, Canada

BobJohnBuoy666 Dec. 22 at 10:50 PM

$CYBN early stage one attempting breakout

0 · Reply

Mastacash Dec. 22 at 9:20 PM

$CYBN 2nd day closing over the 200sma, now testing the 200ema, volume and price action remains strong. Fundamentals are lining up with the technicals, this is exactly what to look for a trend change a breakout.

0 · Reply

Rico_Again_Jorge Dec. 22 at 9:03 PM

$CYBN They are pumping the stock ahead of the name change… then back down again

0 · Reply

Mastacash Dec. 22 at 8:15 PM

$CYBN the longer the stock stays here threatening the 200dma and refuses to pull back, the more the bears and shorts get frustrated, you will see them continue to try and push it down when volume gets light, a sector or market pullback happens. But the price action suggest the bulls are waited below to buy any dip. Literally no big ask orders on level 2, so the only way a bull can accumulate is small orders or wait for a pullback. Everytime a large ask order pops up someone goes up to fill it.

0 · Reply

Gabgoat Dec. 22 at 7:44 PM

$CYBN hello new here why are the analyst so BULLISH about this one ?

1 · Reply

BobJohnBuoy666 Dec. 22 at 5:43 PM

$CYBN pause before 10, we going supernova

0 · Reply

kev90123 Dec. 22 at 5:19 PM

$CYBN HELP...what a perfect new ticker symbol.

0 · Reply

Mastacash Dec. 22 at 2:13 PM

$CYBN https://d18rn0p25nwr6d.cloudfront.net/CIK-0001833141/a9bccec5-b50a-487c-b61f-172af6eb2a08.pdf F10 filing, lots of new info inside, finally the company is providing transparency about spending allocation. Somebody is listening.

0 · Reply

Rico_Again_Jorge Dec. 22 at 12:54 PM

$CYBN Changing a brand tells you all you need to know about the urgency they have to make everyone forget about the past Tainted asset Tainted legacy

0 · Reply

thepalace2007 Dec. 22 at 3:54 AM

$CYBN im a buyer at anything under $15 this will be a $100 stock soon

0 · Reply

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Nov 13, 2025, 3:11 PM EST - 5 weeks ago

Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 7:20 AM EST - 5 weeks ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:30 AM EST - 5 weeks ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 7:30 AM EST - 6 weeks ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 5, 2025, 7:30 AM EST - 6 weeks ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:30 AM EST - 7 weeks ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Oct 31, 2025, 4:19 PM EDT - 7 weeks ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 7 weeks ago

Cybin Announces $175 Million Registered Direct Offering

Oct 21, 2025, 8:00 AM EDT - 2 months ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Sep 23, 2025, 5:00 PM EDT - 3 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 11, 2025, 3:59 PM EDT - 3 months ago

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Sep 11, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 8, 2025, 7:30 AM EDT - 3 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 4, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:30 AM EDT - 3 months ago

Cybin Announces Senior Leadership Changes

Aug 26, 2025, 7:30 AM EDT - 4 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 18, 2025, 5:30 PM EDT - 4 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Aug 13, 2025, 5:30 PM EDT - 4 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 7, 2025, 7:30 AM EDT - 4 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 6, 2025, 7:30 AM EDT - 4 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 17, 2025, 7:30 AM EDT - 5 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 1, 2025, 11:19 AM EDT - 6 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 10:03 PM EDT - 6 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 9:27 PM EDT - 6 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 13, 2025, 7:45 AM EDT - 6 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 12, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 11, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 3, 2025, 7:30 AM EDT - 7 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

May 22, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 20, 2025, 7:30 AM EDT - 7 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 15, 2025, 7:30 AM EDT - 7 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 14, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 8, 2025, 7:30 AM EDT - 8 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 1, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Apr 23, 2025, 7:30 AM EDT - 8 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 21, 2025, 8:00 AM EDT - 8 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Feb 10, 2025, 9:48 PM EST - 11 months ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Jan 15, 2025, 12:07 PM EST - 1 year ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 13, 2025, 7:30 AM EST - 1 year ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 9, 2025, 5:00 PM EST - 1 year ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 10, 2024, 7:30 AM EST - 1 year ago

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Dec 4, 2024, 7:30 AM EST - 1 year ago

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Nov 18, 2024, 7:00 AM EST - 1 year ago

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Nov 14, 2024, 7:30 AM EST - 1 year ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

BobJohnBuoy666 Dec. 22 at 10:50 PM

$CYBN early stage one attempting breakout

0 · Reply

Mastacash Dec. 22 at 9:20 PM

0 · Reply

Rico_Again_Jorge Dec. 22 at 9:03 PM

$CYBN They are pumping the stock ahead of the name change… then back down again

0 · Reply

Mastacash Dec. 22 at 8:15 PM

0 · Reply

Gabgoat Dec. 22 at 7:44 PM

$CYBN hello new here why are the analyst so BULLISH about this one ?

1 · Reply

BobJohnBuoy666 Dec. 22 at 5:43 PM

$CYBN pause before 10, we going supernova

0 · Reply

kev90123 Dec. 22 at 5:19 PM

$CYBN HELP...what a perfect new ticker symbol.

0 · Reply

Mastacash Dec. 22 at 2:13 PM

0 · Reply

Rico_Again_Jorge Dec. 22 at 12:54 PM

$CYBN Changing a brand tells you all you need to know about the urgency they have to make everyone forget about the past Tainted asset Tainted legacy

0 · Reply

thepalace2007 Dec. 22 at 3:54 AM

$CYBN im a buyer at anything under $15 this will be a $100 stock soon

0 · Reply

wifesboyfriends Dec. 22 at 2:16 AM

$CYBN did they even explain why the choose the name?

1 · Reply

Mastacash Dec. 22 at 12:15 AM

$CYBN https://x.com/mastacash_/status/2002894875071594984?s=12&t=jCHCXrWm93J_2H0pU9P1Fw

0 · Reply

Rico_Again_Jorge Dec. 21 at 7:00 PM

$CYBN Soon at your local theater Elusive Pharma

0 · Reply

1iquid Dec. 21 at 3:01 PM

💎 Liquid® Live Actionable Trade Asset: $CYBN Contracts: $CYBN May 15, 2026 $8 Calls Scale in: $1.61- $1.97 Scale out: $6.26-$10.73 Profit Potential : 299% ROI Blended Join 💎 Here: https://1iquid.com

0 · Reply

BinaryLogic Dec. 20 at 6:05 PM

$CYBN [$9.0] Pull back on the 3YR Weekly, and you will see that $9.0 is a consistent support/resistance line for the Company over that time period. $84M in Cash/ST against $42M in Total Liabilities (appx); however, this was prior to its $175M mixed offering at the close of October, which I highlighted at the time. This provides the Company a 2-3YR Cash runway with multiple catalysts in the interim. CBD re-classification provides greater attention (IMO) to psychedelics the same. Industry leading IP, multiple programs in Ph-II and Ph-III development, and conditions to warrants cited acquisition and strike/exercise prices of $8.14 and $19.53 respectively. https://www.msn.com/en-us/money/markets/cybin-to-rebrand-as-helus-pharma-and-shift-us-listing-to-nasdaq/ar-AA1SI3Sn?ocid=finance-verthp-feeds

0 · Reply

_Bennett_ Dec. 20 at 4:12 PM

$CYBN psychedelic biotech sitting low, regulatory or data headlines plus volume are the only things that change this chart

0 · Reply

seacann Dec. 20 at 4:00 PM

$CYBN Nasdaq uplisting and rebanding as Helus Pharma beginning of 2026. $HELP.X 🚀🌕

0 · Reply

BobJohnBuoy666 Dec. 19 at 9:26 PM

$CYBN we closed above the wedge AND the 200EMA…I am flabbergasted. Enough messing around we headed for double digits, SEND IT

0 · Reply

YeOldSalt Dec. 19 at 8:49 PM

$CYBN been holdin this bag for years

2 · Reply

firetypecracker Dec. 19 at 8:46 PM

$CYBN HUGE inflows today...

0 · Reply

SimpleWinningSetups Dec. 19 at 8:13 PM

Hedge Alert Live - Protect Your Portfolio Contract: $CYBN $5.00 Put · JAN 16, 2026 Exp Entry Price: $0.15 - $0.16 Exit Price Target: $0.28 Profit Margin: +87% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Leonewmoon Dec. 19 at 7:06 PM

$CYBN extremely bullish is right 😎

0 · Reply

Market Cap	180.85M
Revenue (ttm)	0.00
Net Income (ttm)	-81.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	640,111
Avg Vol	844,664
Day's Range	N/A - N/A
Shares Out	25.19M
Stochastic %K	98%
Beta	0.67
Analysts	Strong Sell
Price Target	$45.00